Company Overview of Arteriocyte, Inc.
Arteriocyte, Inc., a clinical stage biotechnology company, develops stem cell and tissue engineering based therapies. It offers platelet rich plasma processing, automated cord blood processing, autologous stem cell therapy, allogeneic stem cell therapy, cell delivery and localization, protein co-delivery, cellular expansion, and therapeutic angiogenesis based solutions. The company also provides autologous platelet separator systems, sterile disposables, demineralized bone matrix powder, and demineralized bone matrix gel; and hematopoietic stem cell expansion kits for research applications. In addition, it develops cell therapy and tissue engineering technologies for cardiovascular, orthoped...
7100 Euclid Avenue
Cleveland, OH 44103
Founded in 2004
Key Executives for Arteriocyte, Inc.
Co-Founder and Chief Medical Officer
Chief Financial Officer and Chief Operating Officer
Vice President and General Manager of Research & Development
Vice President of Clinical and Regulatory Affairs
Compensation as of Fiscal Year 2014.
Arteriocyte, Inc. Key Developments
Arteriocyte, Inc. Receives FDA IDE Approval to Initiate Clinical Evaluation of MAGELLAN(R) Bio-Bandage(TM)
May 2 14
Arteriocyte, Inc. announced approval from the Federal Drug Administration (FDA) to initiate a Phase I, clinical trial using its MAGELLAN(R) Bio-Bandage(TM) technology in the treatment of Acute Deep Partial Thickness Thermal Injuries. The FDA Investigational Device Exemption (IDE 15921) allows the company to initiate clinical evaluation of Autologous Platelet Rich Plasma use in thermal injuries. The MAGELLAN(R) Bio-Bandage(TM) is an autologous intervention designed to minimize the severity of the burn wound, reduce the immediate need for surgical intervention when a skin graft is required, and improve the wound's healing trajectory.
Arteriocyte, Inc. Wins BARDA Contract Valued up to $101.1 Million for Advanced Development of Arteriocyte's Magellan(R) BioBandageTM for Thermal Radiation Injury
Sep 26 13
Arteriocyte, Inc. announced that it has been awarded a contract valued at up to $101.1 million (if all contract options are exercised), by the U.S. Department of Health and Human Services. The Biomedical Advanced Research and Development Authority (BARDA) awarded this contract. The contract supports research and development of the Magellan(R) Bio-Bandage(TM) and clinical evaluation to improve the existing standard of care in definitive burn treatments. The award consists of a two-year base contract totaling $11.8 million. If milestones are met, then at BARDA's discretion, additional options may be exercised to support advanced development over the next three years. The total award will support preclinical, clinical, regulatory and additional device modifications to Arteriocyte's existing Magellan(R) technology in order to complete additional FDA approvals for the use of Magellan(R) Bio-Bandage(TM) to treat thermal burn injury.
Arteriocyte Announces Launch of Compass Biomedical
Jun 3 13
Arteriocyte, Inc. announced the launch of Compass Biomedical, the commercial tools division of Arteriocyte that supplies novel cell culturing products and technologies for translational research. As part of the Arteriocyte family, Compass Biomedical has access to the pipeline of cutting edge research from Arteriocyte's research and development team, as well as collaboration partnerships with leading research institutions making Compass Biomedical an ideal choice to help accelerate the transition from basic research to clinical application. Compass Biomedical already supplies 3 product lines: 1) NANEX(TM) Cell Culture and Expansion Kit; 2) Adhere-34(TM) Cell Culture and Expansion Bag; and 3) PLUS(TM) Cell Culture Supplement. Compass Biomedical's core products are based upon the NANEX(TM) biofunctional nanofiber-based technology, that was designed to partially mimic key features of human bone marrow enabling rapid ex vivo cell growth and expansion while maintaining the stem cell's properties. It is an ideal solution for rapidly culturing hematopoietic stem and progenitor cells (HSC/HPCs) for basic research, therapeutics, drug discovery, and screening. These expanded cells have been used to grow new blood cells (including red blood cells and platelets) and new blood vessels. One of the major challenges in cellular therapy research is the limited number of stem cells present in adult human tissues, which today limits the research and clinical applications of stem cell technology. The NANEX(TM) Cell Culture and Expansion Kit has been designed specifically for the ex vivo expansion of human bone marrow, peripheral blood, and umbilical cord blood derived HSCs/HPCs. Adhere-34(TM) incorporates the NANEX(TM) nanofiber technology into a fully closed system, enabling sterile and convenient stem cell culturing and rapid expansion for a variety of applications. Adhere-34(TM) will enable researchers to seamlessly transition from the Research Use Only NANEX(TM) Cell Culture and Expansion Kit (in multi-well plate form) to the closed culture ADHERE-34(TM) system, which was developed specifically for use in clinical protocols. PLUS(TM) Cell Culture Supplement is a cytokine rich replacement for fetal bovine serum (FBS). PLUS(TM) is derived from human platelet lysate and is made using state of the art manufacturing techniques. PLUS(TM) provides a safe, xeno-free serology tested product that minimizes sample variation. PLUS(TM) Cell Culture Supplement has been shown to enhance growth rates of mesenchymal stem cells (MSC) while maintaining key MSC phenotypes when compared to fetal bovine serum.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|